Clinical trial
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary…
NCT00284518 · Allergan, Industry · Completed
Key facts
| NCT number | NCT00284518 |
|---|---|
| Title | Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia |
| Lead sponsor | Allergan, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Benign Prostatic Hyperplasia |
| Intervention type | Biological, Drug |
| Interventions | botulinum toxin Type A, normal saline |
| Enrollment | 380 |
| Start date | Dec 1, 2005 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2010 |
| First posted | Feb 1, 2006 |
| Last update posted | Dec 17, 2012 |
| Countries | Australia, Austria, Canada, Czechia, France, Germany, Italy, Slovakia, South Korea, Taiwan, United Kingdom |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: